Coronary heart disease in patientswith a metabolic syndrome

Authors: Shuvaev I.P., Asymbekova E.U., Buziashvili Yu.I.

Company: Bakoulev National Scientific and Practical Center for Cardiovascular Surgery of Ministry of Health of the Russian Federation; Rublevskoe shosse, 135, Moscow, 121552, Russian Federation

For correspondence:  Sign in or register.


DOI: https://doi.org/10.15275/kreatkard.2017.01.03

For citation: Shuvaev I.P., Asymbekova E.U., Buziashvili Yu.I. Coronary heart disease in patients with a metabolic syndrome. Kreativnaya kardiologiya (Creative Cardiology, Russian journal). 2017; 11 (1): 20–30 (in Russ.). DOI: 10.15275/kreatkard.2017.01.03

Received / Accepted:  February 20, 2017 / February 27, 2017

Keywords: coronary heart disease diabetes mellitus metabolic syndrome

Full text:  

 

Abstract

The rate of ischemic heart disease (IHD) in patients with metabolic syndrome (MS) is more common than in general population. The complications of IHD develop earlier in the setting of MS, than without it. The IHD with concomitant MS and/or diabetes mellitus (DM) has more malignant progressing – up to painless myocardial infarction. Unstable angina, myocardial infarction, heart rhythm disorders are more common in patients with IHD and glycaemia disorders. Congestive heart failure, diffuse lesions of coronary arteries, including distal sites of a coronary bed develop at this category of patients in less time. MS is a risk factor of complications at open heart surgery. The efficiency of treatment in these cases considerably depends on early diagnostics which provides special relevance and importance to a problem of risk factors of metabolic disturbances.

References

  1. Ades P., Panagiotakos D.B., Pitsavos C., Chrysohoou С., Skoumas J. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am. Heart J. 008; 147: 106–12.

  2. Cook S., Weitzman M., Auinger P., Nguyen M., Dietz W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey. Arch. Pediatr. Adolesc. Med. 2014; 157: 821–7.

  3. Fihn S.D., Gardin J.M., Abrams J., Berra K., Blankenship J.C., Dallas P. et al. 2012 ACCF/ AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2014; 60 (24): e44–164.

  4. Rachas A., Raffaitin C., Barberge Gateau P. et al. Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study. Heart. 2012; 98: 650.

  5. Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2013; 32: 1769–818.

  6. Hunt M.E., O’Malley P.G., Feuerstein I., Taylor A.J. The relationship between the “metabolic score” and sub-clinical atherosclerosis detected with electron beam computed tomography. Coron. Artery Dis. 2003; 14 (4): 317–22.

  7. Consensus Russian experts on metabolic syn-drome: definition, diagnostic criteria for primaryprevention and treatment. Consilium Medicum.2010; 12 (5): 5–11 (in Russ.).

  8. Li W., Bai Y., Sun K. et al. Patients with metabolic syndrome have prolonged corrected QT interval (QTc). Clin. Cardiol. 2009; 32: E93–9.

  9. Guerra F., Mancinelli L., Angelini L. et al. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS One. 2011; 6 (1): e16630.

  10. Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular risk in young Finns study. Diabet Med. 2009; 26: 354–61.

  11. Shcherbakova M.Yu., Sinitsyn P.A. Modern viewson the diagnosis, classification, principles of riskand approaches to the treatment of children withmetabolic. Pediatriya. 2010; 89 (3): 123–7 (inRuss.).

  12. Smith S.C., Benjamin E.J., Bonow R.O. et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. A Guideline From the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458–73.

  13. Tanner R.M., Baber U., Carson A.P., Voeks J., Brown T.M., Soliman E.Z. et al. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic And Racial Differences in Stroke [REGARDS] Study). Am. J. Cardiol. 2011; 108 (2): 227–32.

  14. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2007; 112 (17): 2735–52.

  15. Khurs E.M., Andreev P.V., Poddubnaya A.V. et al.Vegetative imbalance in the pathogenesis of themetabolic syndrome. Klinicheskaya meditsina.2010; 88 (6): 39–42 (in Russ.).

  16. Vitarius J.A. The metabolic syndrome and cardiovascular disease. Mount Sinai J. Med. 2005; 72 (4): 257–62.

  17. Mouquet F., Cuilleret F., Susen S., Sautiere K., Marboeuf P., Ennezat P.V. et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulinresistance, adiponectin and plasminogen activator inhibitor-1. Eur. Heart J. 2009; 30 (7): 840–9.

  18. Wijns W., Kolh P., Danchin N. et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014; 31: 2501–55.

  19. Vyssoulis G., Karpanou E., Adamopoulos D., Kyvelou S.M., Tzamou V., Michaelidis A. et al. Metabolic syndrome and atrial fibrillation in patients with essential hypertension. Hypertension Unit, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, Greece. Nutr. Metab. Cardiovasc. Dis. 2013; 23 (2): 109–14.

  20. Sharma S.K., Agrawal S., Damodaran D. et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N. Engl. J. Med. 2011; 365: 2277–86.

  21. Arutyunov G.P. Diabetes mellitus and atheroscle-rosis. What is the optimal strategy of atherosclero-sis control? Serdtse. 2004; 3 (1): 36 (in Russ.).

  22. Reaven G.M., Hollenbeck C.B., Chen Y.D. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia. 1989; 32 (1): 52–5.

  23. Yaturu S., Humphrey S., Landry C., Jain S.K. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med. Sci. Monit. 2009; 15 (1): 5–9.

  24. Kratnov A.E., Klimacheva O.V., Tret'yakov S.V.Effect of metabolic syndrome factors on changes inheart rate variability. Sovremennye tekhnologii vmeditsine.2011; 3: 102–5 (in Russ.).

  25. Trikalinos T.A., Alsheikh-Ali A.A., Tatsioni A., Nallamothu B.K., Kent D.M. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network metaanalysis. Lancet. 2009; 373: 911–8.

  26. Starodubova A.V., Chervyakova Yu.B., Kopelev A.A.,Alieva A.M. Prevention of diabetes mellitus in patientswith carbohydrate metabolism disorders. Lechebnoedelo.2015; 3: 59–65 (in Russ.).

  27. Keren M.A., Yarbekov R.R. Current state andprospects of development of coronary revasculariza-tion in patients with diabetes. Byuletten’ NauchnogoTsentra Serdechno-Sosudistoy Khirurgii imeni A.N.Bakuleva Rossiyskoy Akademii Meditsinskikh Nauk.2015; 16 (1): 4–13 (in Russ.)

About Authors

  • Shuvaev Igor’ Petrovich, MD, PhD, Cardiologist;
  • Asymbekova El’mira Umetovna, MD, DM, Leading Research Associate;
  • Buziashvili Yuriy Iosifovich, MD, DM, Professor, Academician of Russian Academy of Sciences, Chief of Department

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery